Ryan D. Chow, MD, discusses real-world data showing that upfront enfortumab vedotin dose reduction can improve tolerability without affecting survival.
Ryan D. Chow, MD
Advertisement
Ryan D. Chow, MD, is a hematology/oncology fellow at Penn Medicine, the University of Pennsylvania Health System.
Articles by Ryan D. Chow, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
4
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
5